Industry News
Excerpt from the Press Release: OCEANSIDE, Calif., Oct. 29, 2020 /PRNewswire/ — Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today publication on the NIH clinical trials website1 of its newly initiated trial aiming to validate a blood-based diagnostic for predicting suicide risk. The Campbell Score™, which is a patent-pending method of quantifying inflammatory-associated biological markers,…
Read More
Excerpt from the Article: On a Friday afternoon in mid-March 2020, as the emergency department at Massachusetts General Hospital began admitting its first coronavirus patients, attending emergency physician and researcher Michael Filbin recognized an urgent need to quickly learn about the emerging pathogen. With a surge of COVID-19 patients expected in the hospital in the…
Read More
Excerpt from the Press Release: WOBURN, Mass.–(BUSINESS WIRE)–ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a leading innovator in the field of precision medicine for autoimmune diseases, today announced it has launched a Phase 1b study as a multiple ascending dose (MAD) trial. The study is in patients who have type 1 diabetes (T1D), an as yet incurable…
Read More
Excerpt from the Article: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. Specifically, based on a potential safety signal and an unfavorable risk/benefit profile at this time, the IDMC recommends further…
Read More
Excerpt from the Article: In a groundbreaking, world-first clinical trial, a team of researchers from Sunnybrook Health Sciences Centre and University Health Network are using focused ultrasound technology to deliver a therapeutic directly to affected brain regions in patients with Parkinson’s disease (PD). Parkinson’s affects more than 6 million people around the world. It is…
Read More
Excerpt from the Press Release: SAN CARLOS, Calif., Oct. 20, 2020 /PRNewswire/ — IncellDx will collaborate on the SARS-CoV2 Clinical Trial NCT04435522 involving Pfizer’s FDA-approved CCR5 antagonist Maraviroc. The trial “Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2″seeks to establish whether a one week treatment with Maraviroc, used at its approved dosage for…
Read More
Excerpt from the Press Release: BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announces that the company has entered into an agreement with Roche (SIX: RO, ROG; OTCQX:…
Read More
Excerpt from the Press Release: OAKLAND, Calif.–(BUSINESS WIRE)–Fabric Genomics, a global leader in clinical interpretation of genomic data, announced today the launch of Fabric GEM, a novel algorithm that quickly and efficiently identifies the likely genetic cause of rare diseases from next-generation sequencing data – enabling faster diagnosis and the possibility of faster and more…
Read More
Excerpt from the Article: When Moderna began research on a vaccine for the virus now known as SARS-CoV-2 in late January, confirmed cases of infection were largely contained within China and the public health catastrophe that’s since unfolded was a threat, not reality. The prospect of designing, testing, and proving a vaccine within a year…
Read More
Check out the latest from The Readout Loud podcast: “Whose voice rings loudest at the FDA? Is it wise to give hedge funds a blank check? And how will the Biogen saga end? We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Helen Branswell joins us to…
Read More